Study #PA18-1163
The use of Viracor ? CMV T Cell Immunity Panel to Assess the Risk of CMV Infection in Hematopoeitic Cell Transplant Recipients with Low Level CMV Viremia.
MD Anderson Study Status
Enrolling
Treatment Agent
Description
The use of Viracor ? CMV T Cell Immunity Panel to Assess the Risk of CMV Infection in Hematopoeitic Cell Transplant Recipients with Low Level CMV Viremia.
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Unknown Sites
Study phase:
Not applicable
Physician name:
Roy Chemaly
Department:
Infectious Diseases
For general questions about clinical trials:
1-833-612-1742
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.